ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices

ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent serial number (USPN) 11,617,677 on April 4, 2023, an addition to a portfolio of several issued U.S. patents covering the Company’s iterative titration technology featured in its FDA-cleared and patient-preferred Precision Oral Appliance Therapy (OAT) devices. ProSomnus’s intellectual property portfolio now includes 17 issued patents in the United States and other countries, encompassing more than 100 claims, in addition to trademarks, trade secrets and other patent applications in process.

“Our patented iterative titration technology is a cornerstone of our differentiation," said Len Liptak, Co-Founder and Chief Executive Officer of ProSomnus. "Iterative titration enables the mechanism of action for our precision medicine approach to treating Obstructive Sleep Apnea. By eliminating the components used by dental product style devices, iterative titration allows ProSomnus devices to be smaller, stronger and made from Medical Grade Class VI materials, too. This continuation patent strengthens the Company’s deep intellectual property portfolio as we continue meeting a growing demand for our patient-preferred Precision Oral Appliance Therapy.”

ProSomnus’s FDA-cleared, Precision OAT devices are a practical alternative to legacy oral devices and CPAP machines. In clinical studies, ProSomnus devices have demonstrated excellent efficacy and robust patient compliance relative to other treatment options. They reposition and stabilize the jaw during sleep, improving airflow through a patient's pharyngeal space. ProSomnus Precision OAT devices consist of maxillary and mandibular aligners that are precision-manufactured with twin-mated posts, and are digitally milled to be patient-specific. Prescribed advancements can be achieved by removing the current upper- or lower-device arch and inserting the next arch in the mandibular advancement series.

About ProSomnusProSomnus (NASDAQ: OSA) precision intraoral medical devices offer effective, economical, and patient-preferred treatment for patients suffering from Obstructive Sleep Apnea (OSA). ProSomnus is the first manufacturer of mass-customized Precision Oral Appliance Therapy (OAT) devices to treat OSA, which affects over 74 million people in North America and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus’s patented, FDA-cleared devices are a less invasive and more comfortable alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to effective and patient-preferred outcomes. A growing body of research, including studies published by the Journal of Clinical Sleep Medicine and Military Medicine, suggests ProSomnus’s Precision OAT devices are an effective treatment for mild to moderate OSA. Additional clinical research has shown that ProSomnus’s Precision OAT devices mitigate many of the side effects associated with alternative treatments and improve economics for payers and providers. With more than 200,000 devices delivered, ProSomnus’s devices are the most prescribed Precision OAT in the U.S. ProSomnus’s FDA-cleared devices are authorized by the Department of Defense and the U.S. Army, and are often covered by medical insurance, Medicare, and social health programs in key international markets. To learn more, visit www.ProSomnus.com.

Investor ContactMike CavanaughICR WestwickePhone: +1.617.877.9641Email: [e-mail]

Media ContactElizabeth ColemanICR WestwickePhone: +1.203.682.4783Email: [e-mail]